Novavax's Second Booster With Omicron Adapted COVID-19 Shot Shows Encouraging Immune Responses

• Novavax Inc (NASDAQ: NVAX) announced topline results from its Phase 3 trial of updated COVID-19 shot against BA.1 strain meeting the primary strain-change endpoint.

• The data demonstrate that the BA.1 vaccine candidate neutralizing responses in those not previously exposed to COVID-19 were greater than those of the prototype vaccine.

• Immunoglobulin G (IgG) antibody responses against BA.1 and prototype strains showed similar responses across the three vaccine groups.

• Related: FDA Gives Emergency Nod To Novavax's Adjuvanted COVID-19 Booster Dose.

• The BA.5 strain pseudoneutralization responses demonstrated no benefit for the BA.1 or bivalent vaccine candidates compared to the prototype vaccine in the overall trial population.

• Overall, the data demonstrated that the prototype vaccine induced a broad immune response against the original prototype, BA.1, and BA.5 strains.

• Pseudoneutralization responses against BA.5 for the prototype vaccine were comparable to those induced by the more closely matched BA.1 vaccine and bivalent vaccine candidates.

• When given as a second booster dose (fourth dose), all three vaccine formulations were similarly well-tolerated, consistent with the well-established safety profile of the prototype vaccine.

• Price Action: NVAX shares are up 3.01% at $20.01 on the last check Tuesday.

See more from Benzinga

• Avenue Therapeutics Buys Baergic Bio, Beefs Up Central Nervous System-Focused Portfolio

• Ocuphire Pharma Shares Jump After Global Licensing Pact For Nyxol Eye Drops

• What In The World Is Going On With Dogecoin Rival Shiba Inu (SHIB) Falling Suddenly? - SHIBA INU (SHIB/U

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.